Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509172 | 0.81 | — | — | |
| SCHEMBL18896548 | 0.79 | CA1 (0.35) | — | |
| SCHEMBL30972554 | 0.77 | LTA4H (0.38) | — | |
| SCHEMBL21361052 | 0.77 | LTA4H (0.33) | — | |
| SCHEMBL1353684 | 0.76 | NOS1 (0.39) | — | |
| SCHEMBL2580873 | 0.76 | — | — | |
| SCHEMBL10869514 | 0.75 | MGLL (0.34) | MGLL | |
| SCHEMBL13061953 | 0.75 | MGLL (0.34) | MGLL | |
| SCHEMBL372025 | 0.75 | ELANE (0.34) | MGLL | |
| SCHEMBL356572 | 0.75 | MGLL (0.34) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765934-B2 | Methods for conjugating nucleic acids with small molecules | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-07-01 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20120177573-A1 | METHODS FOR CONJUGATING NUCLEIC ACIDS WITH SMALL MOLECULES | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-7449558-B2 | Site-specific labelling of proteins | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2008-11-11 | — | — | US | disclosed |
| US-20050158804-A1 | Site-specific labelling of proteins | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | MGLL 2428/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | MGLL 2428/4885 |
| US-20120177573-A1 | METHODS FOR CONJUGATING NUCLEIC ACIDS WITH SMALL MOLECULES | RNGTT, POLM, POLRMT | MGLL 2813/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | MGLL 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.